Overcoming critical challenges in AI-driven drug discovery
Supported by:
25 November 2024
3:00pm
Shares
- Like
- Digg
- Del
- Tumblr
- VKontakte
- Buffer
- Love This
- Odnoklassniki
- Meneame
- Blogger
- Amazon
- Yahoo Mail
- Gmail
- AOL
- Newsvine
- HackerNews
- Evernote
- MySpace
- Mail.ru
- Viadeo
- Line
- Comments
- Yummly
- SMS
- Viber
- Telegram
- Subscribe
- Skype
- Facebook Messenger
- Kakao
- LiveJournal
- Yammer
- Edgar
- Fintel
- Mix
- Instapaper
- Copy Link
The increasing use of AI in the life science field marks a pivotal point in history. Although AI is now an indispensable tool in drug discovery, promising to save vast amounts of time and money, there are still many hurdles scientists encounter. This webinar will explore these challenges and offer insights into how they can be overcome.
Join us for this webinar as we investigate how challenges in AI-driven drug discovery can be overcome. In this webinar, esteemed experts will explore strategies to improve data collection, integration and curation, the importance of model interpretability and the latest advancements in explainable AI.
Also, our panellists will discuss how scientists can collaborate with regulators to create frameworks that both support innovation and ensure ethical research practices. Furthermore, success stories in bridging the gap between traditional drug discovery methods and AI-driven approaches will be shared.
Key learning points:
- Ensuring data quality and diversity: Our panellists will discuss strategies for improving data collection, integration and curation to ensure AI models are trained on high-quality, unbiased and diverse datasets. They will also explain approaches to managing data scarcity in rare diseases, and how to overcome biases in existing datasets.
- Importance of model interpretability: The latest advancements in explainable AI (XAI) will be elucidated, as well as how these advancements can build trust with regulators, researchers and industry stakeholders.
- Generalisation and transferability of AI models: The challenges of generalising AI models from preclinical animal studies to human applications will be explained, as well as the methodologies for improving the transferability of AI insights.
- Navigating ethical, legal and regulatory landscapes: Our panellists will explore the ethical considerations, data privacy issues and intellectual property challenges associated with AI, and how scientists can work with regulators to create frameworks that both support innovation and ensure ethical research practices.
- Building trust in AI solutions: Despite some scepticism surrounding the adoption of AI, success stories that have bridged the gap between traditional drug discovery methods and AI-driven approaches will be shared.
Register now to secure your place!
Dalip Sethi, Terumo Blood and Cell Technologies As an innovative and transformational scientific leader, Dalip Sethi, PhD, currently serves as the scientific lead for Terumo Blood and Cell Technologies, Cell Therapy Technologies and Innovation portfolio. He holds a doctorate and conducted post-doctoral studies at Thomas Jefferson University, School of Medicine. In his post-doctoral research, Dalip focused on the development of cancer gene-specific RNA and DNA analogs targeted against cancer genes in the signal transduction pathway for use as cancer diagnostics and therapeutics. Throughout his career in the industry, Dalip has been engaged in developing technologies and methods for use in cell therapy applications. Dalip has authored multiple scientific publications and is a co-inventor on several patents and patent applications. He recently co-authored publications on modular automated systems for CD3+ T-cell manufacturing and monoculture of cord-blood derived CD34+ using an automated, membrane-based dynamic perfusion system. The articles highlighted the benefits of modular automation in cell therapy manufacturing. Dalip is also an ISCT member and participates in committees focused on cold chain, particulates, and process analytical technologies. Edward is a Partner in the Sofinnova Digital Medicine Strategy. He joined in 2021 from M Ventures, Merck KGaA’s corporate VC arm, where he focused on investments in cutting-edge digital medicine companies, including developers of the first FDA-approved videogame therapy. Before that, Edward was in the Life Sciences securities team at Kempen & Co, a pan-European merchant bank, covering listed small- and mid-cap life sciences equities. He started his career as an analyst within the biopharma investment team of M Ventures. Edward is positive, energetic and purpose-driven — and he enjoys a challenge. In 2012, for instance, he took on the Gobi Desert in an underpowered 1.2L Chevrolet Aveo, which he and his team drove from London to Mongolia to raise money for SOS Children’s Villages. He holds an MSc in Biopharmaceutical Sciences from Leiden University, The Netherlands, with a specialisation in pharmacology. Simon Turner, Sofinnova Partners– Digital Medicine Strategy Simon is a Partner in the Sofinnova Digital Medicine Strategy. He joined in 2021 after consulting for corporates seeking to develop partnerships with digital health companies. He worked closely with business development functions to identify, assess, and structure strategic investments. Prior to that, Simon was at Baxter International, where he was part of the External Innovation Department. He has worked with various innovation agencies and chaired financing panels. He has a BSc in Biomedical Science from King’s College London and an MSc in International Business from SKEMA Business School. Claudia Zylberberg, Kosten Digital Is the webinar free? When will the webinar take place? I’m busy. Can I watch it later? What are the benefits of attending live? How long will the webinar be? What do I need to watch this webinar? Do I receive a certificate?OUR SPEAKERS
Edward Kliphuis, Partner, Sofinnova Partners – Digital Medicine Strategy 
Simon enjoys constant exposure to novel technologies, curious and motivated people, and supporting the development of companies that are striving to improve medicine. He decided to join Sofinnova because of the strong team spirit and collective drive.FAQs
Yes – there is no charge to watch the webinar, either live or on-demand.
The webinar will take place live on 25 November 2024 at 3PM GMT.
The webinar will become available to watch on-demand shortly after the live webinar takes place.
During the live webinar, you’ll be able to ask the speakers your questions, which will then be answered during the live Q&A session towards the end of the webinar.
This webinar will last for up to one hour.
All you need is a computer with an internet connection. Be sure to use headphones if in an office environment.
Yes, you will receive a certificate if you attend the webinar live. The certificate will be sent with your on-demand video link.